Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Inclusion criteria: 1. T2DM patients and healthy controls aged =18 to \<70 at Visit 1. 2. Patients diagnosed with T2DM according to the American Diabetes Association criteria prior to informed consent who are drug-naïve 3. T2DM patients on a stable dose of allowed concomitant medications (as determined by investigator) for 30 days prior to entering the study. 4. T2DM patients with HbA1c between \>7 and \<10.0% (\>53 mmol/mol and \<86 mmol/mol) at Visit Exclusion criteria: 1. Patients with type 1 diabetes mellitus. 2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater than 240 mg/dl after an overnight fast. 3. Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 3; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease (history of claudication), or pulmonary disease as determined by investigator. 4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.